134 related articles for article (PubMed ID: 26896756)
1. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
Ito J; Suda G; Yamamoto Y; Nagasaka A; Furuya K; Kumagai K; Kikuchi H; Miyagishima T; Kobayashi T; Kimura M; Yamasaki K; Umemura M; Izumi T; Tsunematsu S; Sato F; Tsukuda Y; Terashita K; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
Hepatol Res; 2016 Dec; 46(13):1294-1303. PubMed ID: 26896756
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
Peres-da-Silva A; Brandão-Mello CE; Lampe E
Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Wang Y; Rao HY; Xie XW; Wei L
Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801
[TBL] [Abstract][Full Text] [Related]
4. The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.
Jones BR; Howe AYM; Harrigan PR; Joy JB
Virus Evol; 2018 Jan; 4(1):vex041. PubMed ID: 29362671
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
Iio E; Shimada N; Takaguchi K; Senoh T; Eguchi Y; Atsukawa M; Tsubota A; Abe H; Kato K; Kusakabe A; Miyaki T; Matsuura K; Matsunami K; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
Hepatol Res; 2017 Nov; 47(12):1308-1316. PubMed ID: 28332272
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
Donaldson EF; Harrington PR; O'Rear JJ; Naeger LK
Hepatology; 2015 Jan; 61(1):56-65. PubMed ID: 25123381
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.
Yang S; Xing H; Feng S; Ju W; Liu S; Wang X; Ou W; Cheng J; Pan CQ
Arch Virol; 2018 Feb; 163(2):467-473. PubMed ID: 29143142
[TBL] [Abstract][Full Text] [Related]
8. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Svarovskaia ES; Gane E; Dvory-Sobol H; Martin R; Doehle B; Hedskog C; Jacobson IM; Nelson DR; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
J Infect Dis; 2016 Apr; 213(8):1240-7. PubMed ID: 26603202
[TBL] [Abstract][Full Text] [Related]
9. Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.
Vijgen L; Thys K; Vandebosch A; Van Remoortere P; Verloes R; De Meyer S
Virol J; 2017 May; 14(1):101. PubMed ID: 28569206
[TBL] [Abstract][Full Text] [Related]
10. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.
Peiffer KH; Sommer L; Susser S; Vermehren J; Herrmann E; Döring M; Dietz J; Perner D; Berkowski C; Zeuzem S; Sarrazin C
Hepatology; 2016 Jan; 63(1):63-73. PubMed ID: 26406534
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.
Li Z; Zhang Y; Liu Y; Shao X; Luo Q; Cai Q; Zhao Z
Medicine (Baltimore); 2017 May; 96(19):e6830. PubMed ID: 28489763
[TBL] [Abstract][Full Text] [Related]
12. Computational analysis of naturally occurring resistance-associated substitutions in genes
Wu R; Geng D; Chi X; Wang X; Gao X; Xu H; Shi Y; Guan Y; Wang Y; Jin J; Ding Y; Niu J
Infect Drug Resist; 2019; 12():2987-3015. PubMed ID: 31571951
[TBL] [Abstract][Full Text] [Related]
13. Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil.
Andrade E; Rocha D; Fontana-Maurell M; Costa E; Ribeiro M; Godoy DT; Ferreira AGP; Tanuri A; Brindeiro R; Alvarez P
Genet Mol Biol; 2020; 43(1):e20180237. PubMed ID: 31644681
[TBL] [Abstract][Full Text] [Related]
14. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
Hézode C; Chevaliez S; Scoazec G; Soulier A; Varaut A; Bouvier-Alias M; Ruiz I; Roudot-Thoraval F; Mallat A; Féray C; Pawlotsky JM
Hepatology; 2016 Jun; 63(6):1809-16. PubMed ID: 26853230
[TBL] [Abstract][Full Text] [Related]
15. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
16. Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
Suda G; Kimura M; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Maehara O; Shimazaki T; Morikawa K; Natsuizaka M; Ogawa K; Sakamoto N
Hepatol Res; 2019 Nov; 49(11):1275-1285. PubMed ID: 31261439
[TBL] [Abstract][Full Text] [Related]
17. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.
Uchida Y; Kouyama JI; Naiki K; Sugawara K; Inao M; Imai Y; Nakayama N; Mochida S
Hepatol Res; 2016 Nov; 46(12):1234-1246. PubMed ID: 26878268
[TBL] [Abstract][Full Text] [Related]
18. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.
Chen ZW; Li H; Ren H; Hu P
Sci Rep; 2016 Feb; 6():20310. PubMed ID: 26842909
[TBL] [Abstract][Full Text] [Related]
19. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
[TBL] [Abstract][Full Text] [Related]
20. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
